Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved U.S. FDA last year. It doesn't look good. acpjournals.org/doi/10.7326/M2… Annals of Int Med

It was great fun to work on this preprint with Dr. Robert Lees ibianco @raacampbell Natalia Orlova 🇺🇦 Darcy Peterka @labrigger Dimitri Yatsenko Che-Hang Yu & Adam Packer. Hope this helps many people to characterise their 2p microscopes biorxiv.org/content/10.110…

1/🧵 Lots of fuss and bother about the announcement from Neuralink today about having implanted their tech in a human brain for the first time. bbc.co.uk/news/technolog…

Active neurons can stimulate the clearance of their own metabolic waste by driving changes to ion gradients in the surrounding fluid and by promoting the pulsation of nearby blood vessels go.nature.com/3Td6Kwe

Day 1 for Pangea Bio at #ADPD2024 in Lisbon! I can't wait to discuss our lead compound OT-003's potential for treating PD and other neurodegenerative diseases. Get in touch if you wish to meet and visit us at our poster # 0530 on Friday & Saturday (lnkd.in/e3Dsqx-U).

Check out these exciting startups and the promising work they are doing to promote brain health.

My brand-new lab website is now LIVE! misa-arizono.com Thank you, merci, arigato to everyone who helped me get to this point.

We have open positions for a postdoc and a research assistant in the beautiful city of Edinburgh at the UK Dementia Research Institute! Reach out if you want to know more about either of the positions!

The landscape of small-molecule prodrugs bit.ly/43I3X1U This new review analyses approved prodrugs to reveal trends in their development, highlighting design rationales, indications, mechanisms of API release, chemistry of promoieties and the market impact of prodrugs

Delighted to announce Prof David Attwell (UCL) as Centre Director of our groundbreaking new Centre for Vascular Dementia Research, a partnership with British Heart Foundation!🎉👏 Prof Attwell's extensive experience brings a wealth of leadership & vision to the role👉buff.ly/3PQbDJL

Yes! pubmed.ncbi.nlm.nih.gov/38525480/

Researchers at AD/PD 2024 discussed progress in developing disease-modifying therapies for synucleinopathies. #parkinsonsdisease AD/PD - Advances in Science & Therapy ow.ly/sPMC50RcMUi

Here is a data-driven reorganization of the symptoms in the DSM-5. 🧵1/10

There's never been a disease-modifying drug for Parkinson's disease to slow its progression. Now there may be two emerging. —GLP-1 nejm.org/doi/abs/10.105… NEJM —anti-synuclein antibody nature.com/articles/s4159… NATURE.med

🧠 Curious about how neurons are wired in the human cortex? Our Science Magazine study tested over 7,000 connections and revealed key differences from rodents: "Directed and acyclic synaptic connectivity in the human layer 2-3 cortical microcircuit". 🧵👇science.org/doi/10.1126/sc…

It's #FluorescentFriday! What happens in the brain during normal aging? While most neurons will not shrink, they will lose synapses, the connections between different neurons, which can affect learning and memory. But how do we take these images from primates? (1/5)

Parvalbumin interneuron activity in autism underlies susceptibility to PTSD-like memory formation: iScience cell.com/iscience/fullt…

Hundreds of thousands of potential psychedelics discovered by docking against predicted and real structures of 5-HT2A #psychedelics "AlphaFold2 structures guide prospective ligand discovery" science.org/doi/10.1126/sc…

The state of the art in secondary pharmacology and its impact on the safety of new medicines bit.ly/3WRAWiW This new article discusses best practices in secondary pharmacology screening, including safety-associated targets not covered by most current screening panels

Interested in prodrugs? This review in the June issue analyses approved prodrugs and discusses trends in their development, design rationales, indications, mechanisms of API release, chemistry of promoieties and market impact bit.ly/43I3X1U rdcu.be/dIGPU